Martingale Asset Management L P decreased its stake in LeMaitre Vascular Inc (NASDAQ:LMAT) by 75.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,100 shares of the medical instruments supplier’s stock after selling 38,001 shares during the quarter. Martingale Asset Management L P’s holdings in LeMaitre Vascular were worth $386,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of LeMaitre Vascular by 3.8% in the 4th quarter. BlackRock Inc. now owns 2,265,936 shares of the medical instruments supplier’s stock worth $72,150,000 after purchasing an additional 82,607 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of LeMaitre Vascular by 6.7% in the 4th quarter. Bank of New York Mellon Corp now owns 232,816 shares of the medical instruments supplier’s stock worth $7,412,000 after purchasing an additional 14,698 shares during the period. Rhumbline Advisers boosted its holdings in shares of LeMaitre Vascular by 3.7% in the 4th quarter. Rhumbline Advisers now owns 60,673 shares of the medical instruments supplier’s stock worth $1,932,000 after purchasing an additional 2,138 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new position in shares of LeMaitre Vascular in the 4th quarter worth approximately $322,000. Finally, Arizona State Retirement System boosted its holdings in shares of LeMaitre Vascular by 228.0% in the 4th quarter. Arizona State Retirement System now owns 25,581 shares of the medical instruments supplier’s stock worth $814,000 after purchasing an additional 17,781 shares during the period. Hedge funds and other institutional investors own 72.88% of the company’s stock.
LeMaitre Vascular Inc (LMAT) opened at $36.98 on Friday. LeMaitre Vascular Inc has a 1-year low of $22.16 and a 1-year high of $39.88. The stock has a market capitalization of $687.65, a price-to-earnings ratio of 43.00, a P/E/G ratio of 2.54 and a beta of 0.54.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Investors of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. The ex-dividend date is Wednesday, March 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.76%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s payout ratio is presently 25.58%.
A number of equities analysts recently issued reports on LMAT shares. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, November 10th. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Finally, Canaccord Genuity restated a “hold” rating and set a $33.00 price objective on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. LeMaitre Vascular has an average rating of “Hold” and a consensus target price of $34.00.
In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 30,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $36.19, for a total transaction of $1,085,700.00. Following the completion of the sale, the chairman now directly owns 3,180,709 shares of the company’s stock, valued at approximately $115,109,858.71. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman George W. Lemaitre sold 45,000 shares of LeMaitre Vascular stock in a transaction on Monday, March 5th. The shares were sold at an average price of $34.66, for a total value of $1,559,700.00. Following the sale, the chairman now directly owns 3,225,709 shares of the company’s stock, valued at $111,803,073.94. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,736 shares of company stock valued at $4,866,186. 23.70% of the stock is owned by company insiders.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.